Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as $11.62 and last traded at $11.89, with a volume of 3031714 shares traded. The stock had previously closed at $12.32.

Wall Street Analyst Weigh In

Several research analysts have commented on DYN shares. Baird R W raised Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Piper Sandler decreased their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Royal Bank of Canada reissued an "outperform" rating and set a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Raymond James raised Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Finally, HC Wainwright decreased their price objective on Dyne Therapeutics from $55.00 to $46.00 and set a "buy" rating on the stock in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $48.75.

Dyne Therapeutics Trading Up 1.3 %

The company has a 50 day moving average of $16.03 and a 200 day moving average of $26.82. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -3.48 and a beta of 1.11.

Remove Ads

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. As a group, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,334 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Richard William Scalzo sold 1,455 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now owns 127,078 shares of the company's stock, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,387 shares of company stock valued at $142,789. 20.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC increased its holdings in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company's stock valued at $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Dyne Therapeutics by 47.3% in the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock valued at $244,755,000 after purchasing an additional 2,189,339 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in Dyne Therapeutics in the fourth quarter valued at about $42,408,000. Norges Bank bought a new stake in Dyne Therapeutics in the fourth quarter valued at about $22,384,000. Finally, Point72 Asset Management L.P. increased its holdings in Dyne Therapeutics by 802.3% in the fourth quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company's stock valued at $21,785,000 after purchasing an additional 822,201 shares during the last quarter. Institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.